NLRC3 (NLR family CARD domain containing 3) is a member of the NOD-like receptor (NLR) protein family that functions as a negative regulator of innate immune responses. While most NLR proteins promote inflammation through inflammasome formation, NLRC3 acts primarily as an inhibitory regulator, making it particularly relevant to chronic neuroinflammatory conditions in neurodegenerative diseases[@conti2021].
NLRC3 (NLR family CARD domain containing 3) is a member of the NOD-like receptor (NLR) protein family that functions as a negative regulator of innate immune responses. While most NLR proteins promote inflammation through inflammasome formation, NLRC3 acts primarily as an inhibitory regulator, making it particularly relevant to chronic neuroinflammatory conditions in neurodegenerative diseases[@conti2021].
Structure and Function
NLRC3 contains an N-terminal pyrin domain (PYD), a central NACHT domain with ATPase activity, and multiple C-terminal leucine-rich repeats (LRRs). The LRR domain is thought to mediate autorepression under resting conditions, while the PYD enables interactions with other signaling proteins[@lupfer2022].
Unlike NLRC4 or NLRP3, NLRC3 does not form canonical inflammasomes. Instead, it suppresses inflammatory signaling through multiple mechanisms: direct interaction with adaptor proteins, sequestration of signaling molecules, and competitive inhibition of other NLRs[@mitchell2021].
Role in Neurodegeneration
Alzheimer's Disease
In Alzheimer's disease, NLRC3 expression is dysregulated in brain tissue, particularly in [microglia](/cell-types/microglia-neuroinflammation) surrounding amyloid plaques. Studies suggest that NLRC3 may help limit excessive inflammation in early disease stages, but this protective function appears to decline with disease progression[@liu2022].
The interplay between NLRC3 and other NLR proteins is relevant to AD pathogenesis. [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activation in microglia contributes to neuroinflammation and disease progression. NLRC3 can inhibit NLRP3 activation, and loss of NLRC3 function may exacerbate inflammatory responses to [amyloid-beta](/proteins/amyloid-beta)[@zhang2021].
Parkinson's Disease
NLRC3 may play protective roles in Parkinson's disease through its regulation of inflammatory responses in dopaminergic [neurons](/entities/neurons) and microglia. Animal studies have shown that NLRC3 deficiency leads to increased neuroinflammation and enhanced vulnerability to MPTP-induced dopaminergic toxicity[@chen2022].
Neuroinflammation in Tauopathies
In tauopathies including progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), NLRC3 may modulate the inflammatory response to [tau](/proteins/tau) pathology. Given that microglial activation correlates with disease severity in these conditions, understanding NLRC3's regulatory role is clinically relevant[@wang2021].
Therapeutic Implications
Enhancing NLRC3 function or expression could represent a therapeutic strategy to dampen harmful neuroinflammation while preserving protective immune responses. Small molecules that stabilize NLRC3 or promote its expression are being investigated for neurodegenerative diseases[@johnson2023].
Key Findings
NLRC3 is an inhibitory NLR that suppresses innate immune responses[@conti2021]
NLRC3 expression is altered in AD and PD brain tissue[@lupfer2022]
NLRC3 can inhibit NLRP3 inflammasome activation[@mitchell2021]
NLRC3 deficiency exacerbates neuroinflammation in animal models[@liu2022]
Therapeutic targeting of NLRC3 may benefit neurodegenerative diseases[@zhang2021]